NASDAQ:BDRX - Nasdaq - US59564R8079 - ADR - Currency: USD
1.43
-0.03 (-2.05%)
The current stock price of BDRX is 1.43 USD. In the past month the price decreased by -28.5%. In the past year, price decreased by -92.39%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.09 | 306.02B | ||
AMGN | AMGEN INC | 13.99 | 149.08B | ||
GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
ARGX | ARGENX SE - ADR | 320.54 | 36.40B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
NTRA | NATERA INC | N/A | 20.02B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
BIIB | BIOGEN INC | 7.2 | 17.36B |
Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 21 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
BIODEXA PHARMACEUTICALS-ADR
1 Caspian Point, Caspian Way
Abingdon OXFORDSHIRE GB
Employees: 21
Company Website: https://www.biodexapharma.com/
Investor Relations: http://biodexapharma.com/investors/
Phone: 4401235888300
The current stock price of BDRX is 1.43 USD. The price decreased by -2.05% in the last trading session.
The exchange symbol of BIODEXA PHARMACEUTICALS-ADR is BDRX and it is listed on the Nasdaq exchange.
BDRX stock is listed on the Nasdaq exchange.
7 analysts have analysed BDRX and the average price target is 204 USD. This implies a price increase of 14165.73% is expected in the next year compared to the current price of 1.43. Check the BIODEXA PHARMACEUTICALS-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIODEXA PHARMACEUTICALS-ADR (BDRX) has a market capitalization of 3.66M USD. This makes BDRX a Nano Cap stock.
BIODEXA PHARMACEUTICALS-ADR (BDRX) currently has 21 employees.
BIODEXA PHARMACEUTICALS-ADR (BDRX) has a resistance level at 1.44. Check the full technical report for a detailed analysis of BDRX support and resistance levels.
The Revenue of BIODEXA PHARMACEUTICALS-ADR (BDRX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the BDRX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BDRX does not pay a dividend.
BIODEXA PHARMACEUTICALS-ADR (BDRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-20.5).
The outstanding short interest for BIODEXA PHARMACEUTICALS-ADR (BDRX) is 5.93% of its float. Check the ownership tab for more information on the BDRX short interest.
ChartMill assigns a fundamental rating of 2 / 10 to BDRX. Both the profitability and financial health of BDRX have multiple concerns.
Over the last trailing twelve months BDRX reported a non-GAAP Earnings per Share(EPS) of -20.5. The EPS increased by 98.74% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -48.82% | ||
ROE | -78.14% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 86% to BDRX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 80.32% and a revenue growth -100% for BDRX